These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24922626)

  • 1. B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes.
    Flint KM; Allen LA; Pham M; Heidenreich PA
    J Am Heart Assoc; 2014 Jun; 3(3):e000806. PubMed ID: 24922626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.
    Kociol RD; Horton JR; Fonarow GC; Reyes EM; Shaw LK; O'Connor CM; Felker GM; Hernandez AF
    Circ Heart Fail; 2011 Sep; 4(5):628-36. PubMed ID: 21743005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-type natriuretic peptide may predict prognosis in older adults admitted with a diagnosis other than heart failure.
    Di Marca S; Rando A; Cataudella E; Pulvirenti A; Alaimo S; Terranova V; Corriere T; Pisano M; Di Quattro R; Ronsisvalle ML; Giraffa CM; Giordano M; Stancanelli B; Malatino L
    Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):636-642. PubMed ID: 29625779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk prediction for 30-day heart failure-specific readmission or death after discharge: Data from the Korean Acute Heart Failure (KorAHF) registry.
    Lim NK; Lee SE; Lee HY; Cho HJ; Choe WS; Kim H; Choi JO; Jeon ES; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Cho MC; Oh BH; Park HY
    J Cardiol; 2019 Feb; 73(2):108-113. PubMed ID: 30360893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BNP-guided therapy optimizes the timing of discharge and the medium term risk stratification in patients admitted for congestive heart failure].
    Valle R; Aspromonte N; Carbonieri E; De Michele G; Di Tano G; Giovinazzo P; Cioè R; Di Giacomo T; Milani L; Noventa F; Chiatto M
    Monaldi Arch Chest Dis; 2007 Sep; 68(3):154-64. PubMed ID: 18361212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Biomarkers to Predict Readmission for Congestive Heart Failure.
    Sudharshan S; Novak E; Hock K; Scott MG; Geltman EM
    Am J Cardiol; 2017 Feb; 119(3):445-451. PubMed ID: 27939586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of short-term follow-up BNP in hospitalized patients with heart failure.
    Khanam SS; Son JW; Lee JW; Youn YJ; Yoon J; Lee SH; Kim JY; Ahn SG; Ahn MS; Yoo BS
    BMC Cardiovasc Disord; 2017 Aug; 17(1):215. PubMed ID: 28774268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification.
    Faggiano P; Valle R; Aspromonte N; D'Aloia A; Di Tano G; Barro S; Giovinazzo P; Milani L; Lorusso R; Dei Cas L
    Int J Cardiol; 2010 Apr; 140(1):88-94. PubMed ID: 19321212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discharge BNP is a stronger predictor of 6-month mortality in acute heart failure compared with baseline BNP and admission-to-discharge percentage BNP reduction.
    Omar HR; Guglin M
    Int J Cardiol; 2016 Oct; 221():1116-22. PubMed ID: 27467969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute systolic heart failure with normal admission BNP: clinical features and outcomes.
    Omar HR; Guglin M
    Int J Cardiol; 2017 Apr; 232():324-329. PubMed ID: 28094130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure.
    Khanam SS; Choi E; Son JW; Lee JW; Youn YJ; Yoon J; Lee SH; Kim JY; Ahn SG; Ahn MS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ; Yoo BS
    PLoS One; 2018; 13(11):e0206380. PubMed ID: 30485284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal BNP follow-up as a marker of treatment response in acute heart failure: Relationship with objective markers of decongestion.
    Omar HR; Guglin M
    Int J Cardiol; 2016 Oct; 221():167-70. PubMed ID: 27400316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure.
    Goonewardena SN; Gemignani A; Ronan A; Vasaiwala S; Blair J; Brennan JM; Shah DP; Spencer KT
    JACC Cardiovasc Imaging; 2008 Sep; 1(5):595-601. PubMed ID: 19356487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure.
    Valle R; Aspromonte N; Giovinazzo P; Carbonieri E; Chiatto M; di Tano G; Feola M; Milli M; Fontebasso A; Barro S; Bardellotto S; Milani L
    J Card Fail; 2008 Apr; 14(3):219-24. PubMed ID: 18381185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.
    Logeart D; Thabut G; Jourdain P; Chavelas C; Beyne P; Beauvais F; Bouvier E; Solal AC
    J Am Coll Cardiol; 2004 Feb; 43(4):635-41. PubMed ID: 14975475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
    Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
    Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical status and B-type natriuretic peptide levels in patients with heart failure at hospital discharge.
    Oral I; Mistrík J; Náplava R
    Herz; 2007 Oct; 32(7):583-8. PubMed ID: 17972033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
    Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
    Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of prognostic significance of amino-terminal pro-brain natriuretic Peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure.
    Shenkman HJ; Zareba W; Bisognano JD
    Am J Cardiol; 2007 Apr; 99(8):1143-5. PubMed ID: 17437744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Estimated Plasma Volume at Postdischarge Follow-Up to Predict Recurrent Events in Patients With Heart Failure.
    Balderston JR; Shah KB; Paciulli SC; Gertz ZM
    Am J Cardiol; 2018 Oct; 122(7):1191-1194. PubMed ID: 30241666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.